Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Mariló de Carrillo, Grupo Espanol de Investigacion en Sarcomas
ClinicalTrials.gov Identifier:
NCT01102608
First received: April 12, 2010
Last updated: March 19, 2012
Last verified: March 2012

April 12, 2010
March 19, 2012
March 2008
October 2011   (final data collection date for primary outcome measure)
The efficacy of the neoadyuvant high-dose of ifosfamide and radiotherapy, determined with clinical and pathological responses [ Time Frame: 10 weeks since the inclusion of the patient ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01102608 on ClinicalTrials.gov Archive Site
Global survival, free relapse survival and toxicity [ Time Frame: Until relapse or patient´s death ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma
Phase II Study of Neoadyuvant High-dose Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma and Identification of Response Predictors

To study the activity and toxicity of a neoadjuvant regimen including high-dose ifosfamide in combination with radiotherapy, and subsequent surgery, in high-risk soft tissue sarcomas.

This is a phase II multicenter study designed in two phases. A total of 32 patients will be included in 10 hospitals belonging to the Spanish Group for Research in Sarcomas (GEIS). Selection criteria are: patients with localized soft tissue sarcoma from the extremities or trunk with high-risk features (>5 cm and grade 2-3), or recurrences after prior inadequate surgery. The treatment schedule will be: initial biopsy, 3 cycles of high-dose Ifosfamide, 12 gr/m2 in 5 days, concurrent with Radiotherapy 50 Gy, and subsequent wide surgery. To assess the predictive factors of response to the combination therapy, DNA and RNA extraction will be performed on the pretreatment biopsies. DNA will be used to hybridize Affymetrix GeneChip® Human Mapping 500K Array, which allows for the study of 500000 SNPs throughout the genome. The expression of 39000 RNA transcripts will be evaluated employing the Affymetrix Genechip Human Genome HG-U133 Plus 2.0, and validated by real-time RT-PCR.

Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Soft Tissue Sarcoma
Drug: Ifosfamide
3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
Experimental: 1
Intervention: Drug: Ifosfamide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
December 2011
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients with Advanced Soft Tissue Sarcoma histological proven, potentially resected, located in extremities and trunk for one of the following histological subtypes: leiomyosarcoma, undifferentiated pleomorphic sarcoma, Synovial Sarcoma, Liposarcoma and malignant tumour of peripheral nerve sheath.
  2. Primary tumour:

    1. Size ³ 5 cm of diameter
    2. Histological grade 2-3
    3. Deep location
  3. No distant metastases
  4. Patients must have not been previously treated with Chemotherapy or Radiotherapy on the tumour area.
  5. However patients are eligible with local relapse after previous surgery.
  6. Patients must be £18 and ³ 65 years old.
  7. Patients must have ECOG performance status 0 to 1
  8. Patients must have measurable disease by Recist Criteria.
  9. Absolute neutrophil count ³1,500/mm3, platelet count ³ 100,060 ml/min, creatinine, total bilirubin, ALT and AST £ 1.5 times the upper limit of normal
  10. Signed informed consent prior to any study specific procedures

Exclusion Criteria:

  1. Patients with cerebral metastasis
  2. Pregnant or breast feeding patients.
  3. Active infection or other concomitant severe illness.
  4. Severe psychiatric illness which would not make possible the obtention of the informed consent
  5. Concurrent treatment with other experimental drugs within 30 days prior to study entry.
  6. History of previous treated or diagnosed cancer in the past 5 years, excepting basocellular cell skin cancer, cervix cancer in situ or superficial bladder carcinoma.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT01102608
GEIS15, Nº EudraCT:2007-005755-42
No
Mariló de Carrillo, Grupo Espanol de Investigacion en Sarcomas
Grupo Espanol de Investigacion en Sarcomas
Not Provided
Study Chair: Xavier García del Muro, Doctor Grupo Español de Investigacion en Sarcomas
Grupo Espanol de Investigacion en Sarcomas
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP